康鲁提高了对抗乳腺癌进展的帕克利塔塞尔的疗效
Chun-Ming Chang1,2, Chikondi Jassi3, Wei-Wen Kuo4,5
1Department of General Surgery, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation Hualien 970, Taiwan.
American journal of cancer research
|June 16, 2025
概括
康鲁 (KR) 是一种传统的中国草药,它对乳腺癌具有显著的抗癌作用. 克尔增强了帕克利塔塞尔的疗效,提供了一个有前途的辅助疗法,以改善治疗结果和克服耐药性.
科学领域:
- 综合性瘤学是一种综合性瘤学.
- 翻译医学是一种翻译医学.
- 传统中国草药的药理学 传统中国草药的药理学
背景情况:
- 乳腺癌药物耐药性构成一个重大的临床挑战.
- 传统中国草药 (TCHM) 提出了一种整合性的方法来增强癌症治疗.
- 康鲁 (KR) 是一种TCHM配方,具有潜在的治疗特性.
研究的目的:
- 为了评估KR对乳腺癌的抗癌作用.
- 评估KR在增强帕克利塔塞尔疗效方面的潜力.
- 研究KR在克服帕克利塔克塞尔耐药性的作用.
主要方法:
- 使用乳腺癌细胞系进行体外研究,评估细胞生长,活力,迁移和入侵.
- 在使用乳腺癌异种移植小鼠模型的体内研究.
- 单独和与帕克利塔塞尔联合使用的KR评估.
主要成果:
- 在体外,KR显著抑制了乳腺癌细胞的生长和迁移.
- KR和帕克利塔塞尔的组合表现出协同效应,降低细胞活力并诱导细胞亡.
- 在小鼠模型中,KR增强了帕克利塔塞尔的瘤抑制疗效.
结论:
- 作为一种新的中国草药配方,KR显示出显著的抗癌潜力.
- KR作为一个有前途的辅助疗法,增强了对乳腺癌的帕克利塔塞尔疗效.
- 进一步的翻译性研究是为KR的临床发展作为补充治疗的必要.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...